OBJECTIVE: The aim of this study was to evaluate the expression of topoisomerase IIalpha (TOP2A) in epithelial and stromal cells of ovarian cancer. METHODS: TOP2A expression was analyzed prospectively in normal and tumor epithelial and adjacent stromal cells using quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR) after laser microdissection (n = 38), RNA in situ hybridization (n = 13), and immunohistochemistry (n = 69). RESULTS: TOP2A mRNA was detected by RNA in situ hybridization in all ovarian cancer samples, with stronger hybridization signals in tumor epithelial cells compared to adjacent stromal cells. The same expression pattern was found by immunohistochemistry (P = .0001). Very interestingly, specific change was found in recurrent ovarian cancer after platinum-based chemotherapy: TOP2A expression decreased in tumor epithelial cells of recurrent ovarian cancer compared to primary ovarian cancer (P = .056), whereas it increased in tumor-adjacent stromal cells in carboplatin-treated recurrent tumors compared to primary ovarian cancer (P = .023). CONCLUSION: TOP2A mRNA and protein expression in ovarian cancer exhibits specific patterns in tumor epithelial and adjacent stromal cells, which are differentially modulated after platinum-based chemotherapy. These data support the recently discovered importance of the stromal compartment in tumor progression and suggest that tumor stromal cells might be relevant to the development of chemotherapy resistance in ovarian cancer.
OBJECTIVE: The aim of this study was to evaluate the expression of topoisomerase IIalpha (TOP2A) in epithelial and stromal cells of ovarian cancer. METHODS:TOP2A expression was analyzed prospectively in normal and tumor epithelial and adjacent stromal cells using quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR) after laser microdissection (n = 38), RNA in situ hybridization (n = 13), and immunohistochemistry (n = 69). RESULTS:TOP2A mRNA was detected by RNA in situ hybridization in all ovarian cancer samples, with stronger hybridization signals in tumor epithelial cells compared to adjacent stromal cells. The same expression pattern was found by immunohistochemistry (P = .0001). Very interestingly, specific change was found in recurrent ovarian cancer after platinum-based chemotherapy: TOP2A expression decreased in tumor epithelial cells of recurrent ovarian cancer compared to primary ovarian cancer (P = .056), whereas it increased in tumor-adjacent stromal cells in carboplatin-treated recurrent tumors compared to primary ovarian cancer (P = .023). CONCLUSION:TOP2A mRNA and protein expression in ovarian cancer exhibits specific patterns in tumor epithelial and adjacent stromal cells, which are differentially modulated after platinum-based chemotherapy. These data support the recently discovered importance of the stromal compartment in tumor progression and suggest that tumor stromal cells might be relevant to the development of chemotherapy resistance in ovarian cancer.
Authors: A P Heintz; F Odicino; P Maisonneuve; U Beller; J L Benedet; W T Creasman; H Y Ngan; M Sideri; S Pecorelli Journal: J Epidemiol Biostat Date: 2001
Authors: M D Sternlicht; A Lochter; C J Sympson; B Huey; J P Rougier; J W Gray; D Pinkel; M J Bissell; Z Werb Journal: Cell Date: 1999-07-23 Impact factor: 41.582
Authors: David G Hicks; Brian J Yoder; James Pettay; Eric Swain; Shannon Tarr; Marybeth Hartke; Marek Skacel; Joseph P Crowe; G Thomas Budd; Raymond R Tubbs Journal: Hum Pathol Date: 2005-04 Impact factor: 3.466
Authors: Nuran Bektas Serce; Andreas Boesl; Irina Klaman; Sonja von Serényi; Erik Noetzel; Michael F Press; Arno Dimmler; Arndt Hartmann; Jalid Sehouli; Ruth Knuechel; Matthias W Beckmann; Peter A Fasching; Edgar Dahl Journal: BMC Cancer Date: 2012-12-13 Impact factor: 4.430
Authors: J H Song; S H Kweon; H-J Kim; T-H Lee; W-S Min; H-J Kim; Y-K Kim; S Y Hwang; T S Kim Journal: Br J Cancer Date: 2012-05-24 Impact factor: 7.640
Authors: G Ferrandina; M Petrillo; A Carbone; G Zannoni; E Martinelli; M Prisco; S Pignata; E Breda; A Savarese; G Scambia Journal: Br J Cancer Date: 2008-05-27 Impact factor: 7.640